Skip to content
OpenCapital
Get started

Alnylam Pharmaceuticals ALNY Q3 2025 earnings

Reported October 30, 2025 · Before market open

Revenue$1.2BBeat by $289.6MDiluted EPS$2.90Beat by $2.34
Revenue estimate$959.4M
EPS estimate$0.56

Next report

Jul 30, 2026 (In 2 weeks)
Revenue estimate$1.3B
EPS estimate$1.61

Financials

Q3 2025

Income statement

See full
Revenue$1.2B+149%
Gross profit$1.1B+151%
Operating income$368.0M+578%
Net income$251.1M+325%
EPS (diluted)$1.84+311%

Balance sheet

See full
Cash & equivalents$1.5B+35.4%
Total debt$268.2M-3.6%
Total equity$233.9M+623%
Total assets$4.9B+15.4%

Cash flow

See full
Operating cash flow$325.1M+644%
CapEx$12.1M+190%
Free cash flow$313.0M+692%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$59.77B+69.3%
Enterprise value$58.55B+69.8%
P/E721.9×—
P/S18.6×+1.8×

Profitability

See full
Gross margin84%-2.8pp
Operating margin8.2%+5.4pp
Net margin2.6%+1.4pp
FCF margin6.9%—

Returns & leverage

See full
Return on equity62.2%—
Debt / equity1.1×-7.5×
Current ratio2.5×-0.2×

Segments

By product

See full
AMVUTTRA$685.3M—
GIVLAARI$73.9M—
OXLUMO$52.8M—
ONPATTRO$39.1M—

Versus estimates

Revenue

Q1 2026$1.2BBeat by $51.7MQ4 2025$1.1BMiss by $52.1M
Q3 2025$1.2BBeat by $289.6M
Q2 2025$773.7MBeat by $110.8MQ1 2025$594.2MBeat by $9.0MQ4 2024$593.2MBeat by $10.6M

Diluted EPS

Q1 2026$1.51Beat by $0.64Q4 2025$0.82Miss by $0.34
Q3 2025$2.90Beat by $2.34
Q2 2025$0.32Beat by $0.86Q1 2025-$0.01Beat by $0.88Q4 2024$0.06Beat by $0.68

Ask the moment Alnylam Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Alnylam Pharmaceuticals report Q3 2025 earnings?
Alnylam Pharmaceuticals (ALNY) reported Q3 2025 earnings on October 30, 2025 before market open.
What were Alnylam Pharmaceuticals's Q3 2025 revenue and EPS?
Alnylam Pharmaceuticals reported revenue of $1.2B and diluted EPS of $2.90 for Q3 2025.
Did Alnylam Pharmaceuticals beat estimates in Q3 2025?
Revenue beat the consensus estimate of $959.4M by $289.6M. EPS beat the consensus estimate of $0.56 by $2.34.
How did Alnylam Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 149.3% from $500.9M a year earlier.
Where can I find Alnylam Pharmaceuticals's Q3 2025 SEC filings?
You can read the 10-Q periodic report (0001628280-25-047345) directly on SEC EDGAR. The filing index links above go to sec.gov.